Source: Annual Congress 2007 - Pathogenesis of idiopathic interstitial pneumonia including idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Yosunkaya, K. Uzun, H. Toy, E. Maden, T. Teke, F. Ozer, C. Boburan, C. Korkmaz (Konya, Turkey). The histopathalogical evaluation of administration route of bleomycin in pulmonary fibrosis model and contribution of smoking to development of fibrosis. Eur Respir J 2007; 30: Suppl. 51, 3420

Member's Comments

No comment yet.

Related content which might interest you: The importance of interventional timing in the bleomycin model of pulmonary fibrosis Source: Eur Respir J, 55 (6) 1901105; 10.1183/13993003.01105-2019 Year: 2020 The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis Source: Eur Respir J, 54 (1) 1801771; 10.1183/13993003.01771-2018 Year: 2019 Estimation of antibiotic effect on the development of bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 The effect of smoking to oxidative stress on lung tissue of rats with inhaled and intratracheal bleomycin induced pulmonary fibrosis Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 Clinical features of combined pulmonary fibrosis and emphysema Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Evolution of biomechanical changes in a murine model of bleomycin-induced lung fibrosis: inflammation versus fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 396s Year: 2006 The role of pulmonary structural cells in pulmonary fibrosis in a model of hypersensitivity pneumonitis Source: Annual Congress 2010 - Immune modulation of airways diseases Year: 2010 Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 327s Year: 2006 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema Source: ERJ Open Res, 7 (3) 00316-2021; 10.1183/23120541.00316-2021 Year: 2021 Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Clinical significance of combined pulmonary fibrosis and emphysema Source: International Congress 2017 – ILDs: clinical problems Year: 2017 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Pulmonary fibrosis is associated with emphysema in systemic sclerosis: indirect support for a smoking pathogenesis hypothesis Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009